OptiNose

OptiNose — Q4 2022 Earnings Presentation

22 slides from OptiNose's earnings presentation, Mar 7, 2023

  1. Slide 1: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 7 , 2 0 2 3 EXHIBIT 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this

  3. Slide 3: Key Takeaways

    3 Key Takeaways Chronic sinusitis is a 10-fold market opportunity for XHANCE We refocused our strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS Submitted sNDA to FDA in February which creates potential for approval by December 2023

  4. Slide 4: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis Creates New Growth Opportunities

    4 Successful Development of XHANCE as the First FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Million patie

  5. Slide 5: ReOpen Program Update

    optinose_ ——— ReOpen Program Update

  6. Slide 6: CS Supplemental NDA - Anticipated Next Steps

    6 CS Supplemental NDA - Anticipated Next Steps  As planned, we submitted our supplemental new drug application (sNDA) in pursuit of a new indication in February 2023 - Submission acceptance decision by FDA anticipated by the start of May 2023 - Assuming acceptance and a standard review period FDA’s

  7. Slide 7: Q4 2022 Performance

    optinose_ ——— Q4 2022 Performance

  8. Slide 8: XHANCE New Prescriptions

    8 XHANCE New Prescriptions XHANCE New Prescriptions decreased 7% in Q4 2022 and were flat for Full Year 2022 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intranasal steroid prescriptions b

  9. Slide 9: XHANCE Total Prescriptions

    9 XHANCE Total Prescriptions decreased 8% in Q4 2022 and increased 2% for Full Year 2022 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intranasal steroid prescriptions based on monthly pres

  10. Slide 10: XHANCE Market Share & Prescribers by Prescribing Frequency

    10 XHANCE Market Share & Prescribers by Prescribing Frequency The Market on this slide is defined as the sum of all intranasal steroid prescriptions written by physicians in the XHANCE target physician audience of approximately 21,000 physicians. Estimated based on monthly prescription data from thi

  11. Slide 11: Q4 and Full Year 2022 Financial Update

    Q4 and Full Year 2022 Financial Update

  12. Slide 12: Financial Review – XHANCE Net Revenue

    12 $73.7 $76.3 FY 2021 FY 2022 Financial Review – XHANCE Net Revenue XHANCE Net Revenue Decreased 7% from Q4 2021 to Q4 2022 and Increased 4% for Full Year 2022 $22.5 $20.9 Q4 '21 Q4 '22 ($M) -7% Net Revenue Net Revenue +4% ($M)

  13. Slide 13: Financial Review – XHANCE Average Net Revenue per Prescription

    13 $240 $242 Q4 '21 Q4 '22 Financial Review – XHANCE Average Net Revenue per Prescription XHANCE Average Net Revenue per TRx Increased from $240 to $242 from Q4 2021 to Q4 2022 and from $219 to $224 for Full Year 2022 $219 $224 FY 2021 FY 2022 +2% Average Net Revenue per TRx Average Net Revenue per

  14. Slide 14: 2023 Outlook

    optinose_ ——— 2023 Outlook

  15. Slide 15: Full Year and Q1 2023 Financial Guidance

    15 Full Year and Q1 2023 Financial Guidance  Operating Expense (GAAP) ‒ Actions taken to reduce FY 2023 operating expenses by ~$30 million compared to FY 2022 actual of $123 million ‒ Expected to be between $90 to $95 million; approximately $8 million of which represents stock-based compensation 

  16. Slide 16: Closing Remarks

    optinose_ ——— Closing Remarks

  17. Slide 17: Key Takeaways

    17 Key Takeaways Chronic sinusitis is a 10-fold market opportunity for XHANCE We refocused our strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS Submitted sNDA to FDA in February which creates potential for approval by December 2023

  18. Slide 18: Investor Relations – Optinose Investor Contact

    18 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267-521-0531 [email protected] As of December 31, 2022: – $94.2 million in cash – Debt: $130 million – 111.5 million common shares o/s – 43.6 million options, warrants

  19. Slide 19: Appendix - ReOpen Program Co-Primary Endpoints

    Appendix - ReOpen Program Co-Primary Endpoints

  20. Slide 20: Combined Symptom Score (Co-Primary Endpoint)

    20 Combined Symptom Score (Co-Primary Endpoint) Improvement in combined symptoms with XHANCE; Consistent with NAVIGATE I and II 1 -0.81 -1.54* -1.74‡ -2.0 -1.8 -1.6 -1.4 -1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS-placebo BID OPN-375

  21. Slide 21: Average of Percentages of Opacified Volume (Ethmoid and Maxillary)

    21 Average of Percentages of Opacified Volume (Ethmoid and Maxillary) Objective Evidence of Effect in Sinus Cavities by CT Scan; Co-Primary Endpoint 1.19 -7.00‡ -5.14♰ -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to

  22. Slide 22: Building a Leading ENT / Allergy Specialty Company

    Building a Leading ENT / Allergy Specialty Company C o r p o r a t e P r e s e n t a t i o n M a r c h 7 , 2 0 2 3

Optinose — Q4 2022 Earnings Presentation on 6ix